Company Description
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.
The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.
It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older.
In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection.
Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus.
The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023.
Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.
| Country | United Kingdom |
| Founded | 2016 |
| IPO Date | Apr 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 130 |
| CEO | William J. Enright MBA |
Contact Details
Address: Unit 6-10, Zeus Building, Rutherford Avenue, Harwell Didcot, X0 OX11 0DF United Kingdom | |
| Phone | 44 (0) 1865 818808 |
| Website | barinthusbio.com |
Stock Details
| Ticker Symbol | BRNS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001828185 |
| ISIN Number | US91864C1071 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| William J. Enright MBA | Chief Executive Officer and Director |
| Dr. Nadege Pelletier Ph.D. | Chief Scientific Officer |
| Graham Griffiths | Chief Business Officer |
| Sarah Gilbert | Co-Founder |
| Adrian Hill Ph.D. | Co-Founder and Scientific Advisor |
| Gemma Brown | Chief Financial Officer and Company Secretary |
| Elizabeth Eagling-Vose M.B.A. | Head of Clinical Operations |
| Bernie McDonald | Head of IP |
| Geoffrey Lynn | Senior Vice President of Synthetic Immunotherapies |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 22, 2024 | ARS | Filing |
| Mar 22, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 22, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 20, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 20, 2024 | 10-K | Annual Report |
| Mar 20, 2024 | 8-K | Current Report |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 5, 2024 | 8-K | Current Report |
| Dec 22, 2023 | 8-K | Current Report |
| Nov 9, 2023 | 8-K | Current Report |